204376-55-6

Basic information

• Product Name: 1-FMOC-4-PIPERIDONE
• Synonyms: 4-Oxo-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester;(9H-Fluoren-9-yl)Methyl 4-oxopiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-oxo-, 9H-fluoren-9-ylMethyl ester;N-FMoc-4-piperidone;1-[[[(9H-Fluoren-9-yl)methyl]oxy]carbonyl]-4-piperidone;N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-4-piperidone;Fmoc-4-piperidone98+%
• CAS NO: 204376-55-6
• Molecular Formula: C₂₀H₁₉NO₃
• Molecular Weight: 321.38
• Mol File: 204376-55-6.mol

Chemical Properties

• Melting Point: 131.0 to 135.0 °C
• Boiling Point: 510.4 °C at 760 mmHg
• Flash Point: 262.5 °C
• Appearance: /
• Density: 1.255 g/cm³
• Vapor Pressure: 1.55E-10mmHg at 25°C
• Refractive Index: 1.616
• Storage Temp.: Store at 0-5°C
• PKA: -1.66±0.20(Predicted)
• BRN: 8857729
• CAS DataBase Reference: 1-FMOC-4-PIPERIDONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-FMOC-4-PIPERIDONE(204376-55-6)
• EPA Substance Registry System: 1-FMOC-4-PIPERIDONE(204376-55-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 204376-55-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Fmoc-4-piperidone is used as a key intermediate in the synthesis of pharmaceuticals for its ability to facilitate the production of complex organic molecules. Its versatility in organic synthesis allows for the creation of a wide range of bioactive compounds, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
1-Fmoc-4-piperidone is used as a building block in the synthesis of agrochemicals, enabling the production of effective and targeted pesticides, herbicides, and other agricultural chemicals. Its role in organic synthesis aids in the development of safer and more efficient agrochemicals to support sustainable agriculture.
Used in Organic Synthesis:
1-Fmoc-4-piperidone is used as a versatile intermediate in organic synthesis for its ability to form a variety of complex organic molecules. Its chemical properties make it suitable for the synthesis of a wide range of compounds, including pharmaceuticals, agrochemicals, and other fine chemicals.
Used in Peptide and Peptidomimetic Library Construction:
1-Fmoc-4-piperidone is used as a building block for the construction of peptide and peptidomimetic libraries, providing a foundation for the development of novel peptide-based therapeutics and drug candidates. Its role in library construction allows for the exploration of new peptide sequences and the discovery of potential bioactive compounds.
Used in Precursor Synthesis:
1-Fmoc-4-piperidone serves as a precursor for the synthesis of various bioactive compounds and pharmaceuticals, enabling the production of new and innovative drugs. Its position as a precursor allows for the development of compounds with unique properties and therapeutic potential, contributing to the advancement of pharmaceutical research and development.

InChI:InChI=1/C20H19NO3/c22-14-9-11-21(12-10-14)20(23)24-13-19-17-7-3-1-5-15(17)16-6-2-4-8-18(16)19/h1-8,19H,9-13H2

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 41979-39-9 4-piperidone hydrochloride 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 351184-42-4 9H-fluoren-9-ylmethyl 4-hydroxy-1-piperidinecarboxylate 

Downstream Products

• 1579291-48-7 (9H-fluoren-9-yl)methyl 4-(2-Azidophenyl)-5,6-dihydropyridine-1(2H)-carboxylate 

Relevant articles and documents

Mio- and Dio-Fmoc - Two modified Fmoc protecting groups promoting solubility

Two novel Fmoc-derived protecting groups, Mio-Fmoc and Dio-Fmoc, were developed, which cause dramatically enhanced solubility of the corresponding derivatives in most organic solvents. Furthermore, the suitability of these groups in solid-phase peptide synthesis was highlighted. Georg Thieme Verlag Stuttgart.

ANTI-CD25 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF

The present disclosure provides anti-CD25 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

ANTI-CD37 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF

The present disclosure provides anti-CD37 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES, COMBINATIONS, AND METHODS OF USE THEREOF

The present disclosure provides methods for treating a cancer or resistant cancer with a combination of an anti-CD22 antibody-maytansine conjugate and one or more anti-cancer agents. The disclosure also encompasses methods for sensitizing a cancer with such combinations. Also provided are pharmaceutical compositions including such combinations.

ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF

The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

ANTI-HER2 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF

The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE

The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. Aspects of the present disclosure include a pharmaceutical composition. The pharmaceutical composition includes a conjugate as described herein and a pharmaceutically acceptable excipient. Aspects of the present disclosure include a method of delivering a conjugate to a subject. The method includes administering to the subject an effective amount of a conjugate as described herein. Aspects of the present disclosure include a method of treating a condition in a subject.

Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor

A novel class of N-substituted 4-hydrazino piperidine derivatives were designed, synthesized and evaluated for DPP IV inhibition. The SAR studies on the N-substituted piperidine led to the discovery of compound 22e as a potent DPP IV inhibitor (IC50 88 nM), which is highly selective over other peptidases. In vivo efficacy indicates that compound 22e stimulates insulin release in response to glucose load and improves glucose tolerance in n5-STZ and Zucker Diabetic Fatty (ZDF) rats.

Oligospiroketals as novel molecular rods

A modular approach for the synthesis of molecular rods based on oligospiroketals has been developed. The strategy relies on different terminal and intermediate segments, which are joined by ketal formation between ketones and diols. For this purpose it was necessary to develop a new ketalization method to circumvent some problems related with the established methods. The terminal segments are either derived from 4-piperidinone or from 4-oxocyclohexane carboxylic acid whereas the intermediate segments rest on pentaerythritol and cyclohexane-1,4-dione. A series of trispiro (14-18), hexaspiro (19) and nonaspiro (20) compounds have been prepared and characterized. From these we realized that it is imperative to use solubility enhancing groups if more than seven rings are joined.

AZOLIDINECARBONITRILES AND THEIR USE AS DPP-IV INHIBITORS

The invention discloses a novel heterocyclic compounds that falls within f the ambit of general formula (I), its stereoisomers, pharmaceutically acceptable salts or solvates wherein X, n,k,z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (i) normalizing elevated blood pglucose levels in diabetes, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals of mammals. The invention also discloses pharmaceutically acceptable composition comprising these compounds, method for preparation of the compounds as defined bove and method of treating mammals including human beings by administering an effective amount of said compounds to a subject in need thereof. The invention further discloses use of these compounds in the manufacture of a medicament useful for treatment of different disease conditions as stated above.